Related Experiment Video
Updated: Apr 14, 2026
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and
You-Wei Li1, Zheng-Guang Chen1, Ji-Chen Wang1
1You-Wei Li, Department of Radiology, Beijing Chuiyangliu Hospital Affiliated to School of Medicine, Tsinghua University, Beijing 100022, China.
Aim:
To evaluate the performance of superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance imaging (MRI) in the detection and characterization of focal hepatic lesions (FHLs).
Methods:
This meta-analysis compared relevant studies that were identified by searching PubMed, EMBASE, and the Cochrane Library databases for articles published between January 1988 and September 2014 and that met the following criteria: (1) SPIO-enhanced MRI was conducted to identify FHLs and data were sufficient for pooled analysis using Meta-DiSc 1.4; (2) hepatocellular carcinomas (HCCs) were differentiated from other FHLs; (3) well-differentiated HCCs (WD-HCCs) were contradistinguished from dysplastic nodules; and (4) WD-HCCs were compared with moderately and poorly differentiated HCCs (MD- and PD-HCCs, respectively).
Results:
The data obtained from 15 eligible studies yielded a sensitivity of 85% and a specificity of 78% for differentiating between HCCs and other FHLs. The sensitivity was unchanged and the specificity was increased to 87% when non-HCC malignancies were excluded. Comparative analyses between WD-HCCs and MD- and PD-HCCs from seven studies showed a sensitivity of 98% and a specificity of 50% for the diagnosis of MD- and PD-HCCs, and the area under the summary receiver operating characteristics (sROC) curve was 0.97. A comparison between WD-HCCs and dysplastic nodules revealed a sensitivity of 50% and a specificity of 92% for the diagnosis of WD-HCCs and the area under the sROC curve was 0.80.
Conclusion:
SPIO-enhanced MRI is useful in differentiating between HCCs and other FHLs.
Insights
Superparamagnetic iron oxide (SPIO)-enhanced MRI effectively detects focal hepatic lesions (FHLs). This imaging technique shows promise in differentiating hepatocellular carcinomas (HCCs) from other FHLs and distinguishing between different grades of HCC.
Area of Science:
- Medical Imaging
- Hepatology
- Oncology
Background:
- Focal hepatic lesions (FHLs) require accurate detection and characterization for effective management.
- Superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance imaging (MRI) offers potential advantages in liver lesion assessment.
Purpose of the Study:
- To evaluate the diagnostic performance of SPIO-enhanced MRI in identifying and characterizing FHLs.
- To assess the ability of SPIO-enhanced MRI to differentiate hepatocellular carcinomas (HCCs) from other FHLs.
- To distinguish between different grades of HCC and dysplastic nodules.
Main Methods:
- A meta-analysis of 15 eligible studies published between January 1988 and September 2014.
- Searched PubMed, EMBASE, and Cochrane Library databases for relevant SPIO-enhanced MRI studies.
- Pooled analysis using Meta-DiSc 1.4 to evaluate diagnostic accuracy for various lesion differentiations.
Main Results:
- SPIO-enhanced MRI demonstrated 85% sensitivity and 78% specificity for differentiating HCCs from other FHLs.
- Excluding non-HCC malignancies improved specificity to 87%.
- High accuracy (sROC AUC 0.97) was observed in differentiating well-differentiated HCCs from moderately/poorly differentiated HCCs, and good performance (sROC AUC 0.80) for distinguishing well-differentiated HCCs from dysplastic nodules.
Conclusions:
- SPIO-enhanced MRI is a valuable tool for differentiating between HCCs and other FHLs.
- The technique aids in characterizing the grade of hepatocellular carcinoma.
- Further research may refine its role in liver lesion diagnosis.
Related Concept Videos
01:24Magnetic Resonance Imaging
01:27Imaging Studies IV: Magnetic Resonance Imaging